News about Market

Glenmark Pharma USA Launches Generic Milnacipran Tablets

Glenmark Pharmaceuticals USA has launched Milnacipran Hydrochloride tablets in multiple strengths as the authorised generic of Savella, expanding treatment access in the US market.

Market | 20/03/2026 | By News Bureau

Natco to Launch Semaglutide Generic at 90 Percent Discount in India

Natco Pharma is set to launch a generic version of semaglutide in India at a sharply reduced price, signalling the start of an intense price competition in the diabetes and weight-loss drug segment.

Market | 20/03/2026 | By Darshana |  147

Novartis Signs Deal with Synnovation Therapeutics to Explore Next-Gen Breast Cancer Treatment

Novartis has signed a deal with Synnovation Therapeutics to advance SNV4818, a next-generation PI3Kα inhibitor in phase-I/II trials, targeting HR+/HER2- breast cancer patients with PIK3CA mutations, addressing a significant unmet need.

Market | 20/03/2026 | By News Bureau

Glenmark Pharma USA Introduces Potassium Phosphates Injection USP

Glenmark Pharmaceuticals USA is set to launch Potassium Phosphates Injection USP in March 2026.

Market | 19/03/2026 | By News Bureau

Strides Pharma Acquires Sandoz's Generic Brands to Expand African Business

Strides Pharma has acquired multiple generic brands from Sandoz to expand its African business, a move expected to position it among the top five pharma companies in Sub-Saharan Africa and more than double its regional presence.

Market | 19/03/2026 | By News Bureau

Leveragen Teams Up with Daiichi Sankyo for Next-Gen Biologics Innovation

Daiichi Sankyo will collaborate with Leveragen to apply its in-vivo antibody discovery platform across selected research programmes, supporting early-stage and pre-clinical development of antibody-based biologics across multiple therapeutic areas.

Market | 19/03/2026 | By News Bureau |  106

Zydus and Torrent Pharma Sign Licensing Deal to Co-Market Semaglutide in India

Zydus Lifesciences and Torrent Pharmaceuticals have entered a licensing agreement to co-market Semaglutide injection in India, aiming to improve access for patients with poorly controlled Type 2 Diabetes Mellitus and support chronic weight management through advanced, innovative therapy.

Market | 19/03/2026 | By News Bureau |  173

Akums Drugs and Pharmaceuticals Launches World's First Lasmiditan Dispersible Tablets for Acute Migraine Treatment

Akums Drugs and Pharmaceuticals introduces DCGI-approved Lasmiditan dispersible tablets, offering faster, patient-friendly migraine relief with improved compliance, especially for patients facing nausea and difficulty swallowing during acute attacks.

Market | 18/03/2026 | By News Bureau |  121

Lupin and Zydus Partner to Co-Market Semaglutide Injection in India

Lupin has secured semi-exclusive rights to co-market Zydus’ Semaglutide injection in India under the brands Semanext and Livarise, while Zydus will continue marketing it under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.

Market | 18/03/2026 | By News Bureau |  212

Argo Biopharma's siRNA Therapy BW-20805 Gets FDA Fast Track for HAE

Argo Biopharma has received FDA Fast Track designation for BW-20805, with an ongoing global phase-II study in adult HAE patients and primary completion expected in the second half of 2026.

Market | 17/03/2026 | By News Bureau